Breast Follows Lung In Another Survival Blow To AstraZeneca and Daiichi Sankyo’s Dato-DXd

AstraZeneca claims the disappointing Phase III TROPION-Breast01 trial result may have been undermined by Enhertu’s new use in HER2-low patients.